Back to results
US 11,195,594 B2Granted
Method for selecting anticancer agent based on protein damage information of individual to prevent anticancer agent side effects
AssigneeCipherome, Inc.
InventorJu Han Kim
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method and a system for selecting an anticancer agent based on protein damage information of an individual by using individual genome sequencing. The method and the system, according to the present invention, are highly reliable and widely applicable techniques capable of predicting side effects or risks of specific drugs, in other words, anticancer agents, for each individual by performing sequence analysis of an exon part of a gene that codes various proteins involved in pharmacokinetics or pharmacodynamics of anticancer agents.
Claims18
A method for providing information for selecting an anticancer agent using individual genome sequence variation, the method comprising:
- determining gene sequence variation information of one or more genes involved in pharmacodynamics or pharmacokinetics of an anticancer agent from individual genome sequence information;
- calculating a gene sequence variation score using the gene sequence variation information, the gene sequence variation score being a numerical score indicating a degree of variation in one of the one or more genes that causes an amino acid sequence variation in a protein encoded by the gene or causes a transcription control variation, thereby causing change or damage to a structure or function of the protein;
- calculating an individual protein damage score using [Equation 2], wherein [Equation 2] is
- S
- g
-
- (
- v
- 1
- ,
- …
-
- ,
- v
- n
- )
- =
- (
- ∏
- i
- =
- 1
- n
-
-
- v
- i
- w
- i
- )
- 1
- ∑
- i
- =
- 1
- n
-
- w
- i
- wherein Sg is a protein damage score of a protein encoded by a gene g, n is the number of target sequence variations to be analyzed among sequence variations of the gene g, vi is a gene sequence variation score of an i-th sequence variation and wi is a weighting assigned to the gene sequence variation score vi of the i-th sequence variation;
- calculating an individual drug score using [Equation 4], wherein [Equation 4] is:
- S
- d
-
- (
- g
- 1
- ,
- …
-
- ,
- g
- n
- )
- =
- (
- ∏
- i
- =
- 1
- n
-
-
- g
- i
- w
- i
- )
- 1
- ∑
- i
- =
- 1
- n
-
- w
- i
- wherein Sd is a drug score of a drug d, n is the number of proteins encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug d, gi is a protein damage score of a protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug d and wi is a weighting assigned to the protein damage score gi of the protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug d;
- and
- providing the individual drug score for use in drug selection among anticancer agents.
77 more elements
A system for selecting an anticancer agent using individual genome sequence variation, the system comprising:
- a database from which information relevant to a gene or protein related to an anticancer agent applicable to an individual can be searched or extracted;
- a communication unit which is accessible to the database;
- a non-transitory computer-readable medium storing computer instructions executable by computer, the computer instructions comprising:
- (i) a first computer instruction configured to calculate gene sequence variation information of one or more genes involved in pharmacodynamics or pharmacokinetics of the anticancer agent based on the information;
- (ii) a second computer instruction configured to calculate a gene sequence variation score using the gene sequence variation information, the gene sequence variation score being a numerical score indicating a degree of variation in the gene that causes an amino acid sequence variation in a protein encoded by the gene or causes a transcription control variation, thereby causing change or damage to a structure or function of the protein;
- (iii) a third computer instruction configured to calculate an individual protein damage score using [Equation 2], wherein [Equation 2] is
- S
- g
-
- (
- v
- 1
- ,
- …
-
- ,
- v
- n
- )
- =
- (
- ∏
- i
- =
- 1
- n
-
-
- v
- i
- w
- i
- )
- 1
- ∑
- i
- =
- 1
- n
-
- w
- i
- wherein Sg is a protein damage score of a protein encoded by a gene g, n is the number of target sequence variations to be analyzed among sequence variations of the gene g, vi is a gene sequence variation score of an i-th sequence variation and wi is a weighting assigned to the gene sequence variation score vi of the i-th sequence variation;
- and
- (iv) a fourth computer instruction configured to calculate an individual drug score by using [Equation 4], wherein [Equation 4] is:
- S
- d
-
- (
- g
- 1
- ,
- …
-
- ,
- g
- n
- )
- =
- (
- ∏
- i
- =
- 1
- n
-
-
- g
- i
- w
- i
- )
- 1
- ∑
- i
- =
- 1
- n
-
- w
- i
- wherein Sd is a drug score of a drug d, n is the number of proteins encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug d, gi is a protein damage score of a protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug d and wi is a weighting assigned to the protein damage score gi of the protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug d;
- and
- a display unit which is configured to display information regarding the calculated scores for use in drug selection among anticancer agents.
81 more elements
A non-transitory computer-readable medium including computer instructions for execution by a processor to perform an operation comprising:
- acquiring gene sequence variation information of one or more genes involved in pharmacodynamics or pharmacokinetics of an anticancer agent from individual genome sequence information;
- calculating a gene sequence variation score using the gene sequence variation information, the gene sequence variation score being a numerical score indicating a degree of variation in one of the one or more genes that causes an amino acid sequence variation in a protein encoded by the gene or causes a transcription control variation, thereby causing change or damage to a structure or function of the protein;
- calculating an individual protein damage score using [Equation 2], wherein [Equation 2] is
- S
- g
-
- (
- v
- 1
- ,
- …
-
- ,
- v
- n
- )
- =
- (
- ∏
- i
- =
- 1
- n
-
-
- v
- i
- w
- i
- )
- 1
- ∑
- i
- =
- 1
- n
-
- w
- i
- wherein Sg is a protein damage score of a protein encoded by a gene g, n is the number of target sequence variations to be analyzed among sequence variations of the gene g, vi is a gene sequence variation score of an i-th sequence variation and wi is a weighting assigned to the gene sequence variation score vi of the i-th sequence variation;
- and
- calculating an individual drug score using [Equation 4], wherein [Equation 4] is:
- S
- d
-
- (
- g
- 1
- ,
- …
-
- ,
- g
- n
- )
- =
- (
- ∏
- i
- =
- 1
- n
-
-
- g
- i
- w
- i
- )
- 1
- ∑
- i
- =
- 1
- n
-
- w
- i
- wherein Sd is a drug score of a drug d, n is the number of proteins encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug d, gi is a protein damage score of a protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug d and wi is a weighting assigned to the protein damage score gi of the protein encoded by one or more genes involved in the pharmacodynamics or pharmacokinetics of the drug d;
- and
- providing the individual drug score for use in drug selection among anticancer agents.
78 more elements
Dependencies are inferred from the claim text.